AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and ...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and CanadaC-BEYOND Topline Results Expected ...

Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low ...

Pharmacological treatment is recommended for patients with chronic HCV infection, advanced fibrosis, compensated cirrhosis, liver transplant, severe extrahepatic manifestations, HIV co-infection, or ...

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s recent authorization of a rapid, point-of-care test to diagnose current hepatitis C virus infection is ...

A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...

Researchers at the University of Washington have developed a rapid test that quickly detects hepatitis C, but insurance ...

Hepatitis C is a serious condition that can greatly affect your liver and overall health. The culprit is a virus called hepatitis C virus (HCV), which typically gets into a person’s system through ...